Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 63
Selected: 0
NCT IDTitle
NCT02425306Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
NCT00293215Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
NCT00803569Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
NCT00291473Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
NCT00006046Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00520533Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
NCT00291447111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
NCT02963831A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
NCT00199797Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT00679289Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
NCT02659540Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
NCT02334735A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
NCT00145145Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
NCT00199875Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
NCT00291486Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
NCT00518206Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
NCT01810016NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
NCT01838200Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
NCT01975831A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
NCT01220999A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
NCT00299728NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
NCT02643303A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
NCT00106158Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
NCT00112242Immunotherapy of Stage III/IV Melanoma Patients
NCT06518837Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT00199849NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
NCT00070070Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
NCT00623831A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
NCT00112957Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00616941Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02898116Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
NCT03017326Paediatric Hepatic International Tumour Trial
NCT00072410Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
NCT01266018Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
NCT00292045Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
NCT03164772Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
NCT02336165Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
NCT02061449Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NCT01079741Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
NCT01380145MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
NCT00199836A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
NCT00199901Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
NCT02252211Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
NCT04729543MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
NCT05736367Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT02431559Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
NCT00006099Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
NCT00112229Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
NCT00520299Study of ADI-PEG 20 in Patients With Advanced Melanoma
NCT02735239Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer